|
|
 |
|
Viewing report
|
|
|
|
China Osteoporosis Market Analysis and Forecast, 2007 - 2015
Transparency Market Research, Jan 2012, Pages: 28
The Chinese Osteoporosis drug market is expected to grow at a CAGR of 14.4% from 2007 to 2015.
Increased prevalence of Osteoporosis among Chinese female population is the principal growth driver of the Osteoporosis drug market. The other key growth drivers for Chinese Osteoporosis market include increasing elderly aged population, rising living standards of the Chinese people and increasing awareness and bone health education.
Geographical analysis of Chinese Osteoporosis drug market shows that there is a huge growth potential for Osteoporosis drug in many cities including Shanghai, Beijing, Guangzhou, and Hangzhou.
Bisphosphonate is the leading Osteoporosis drug class in China for Osteoporosis treatment and is expected to remain so for next few years.
To gain a competitive advantage, market players should develop cost-competitive drugs with easy dosage pattern, which promote bone building effectively.
Large numbers of patients are unable to comply with the strict dosage schedule of traditional Osteoporosis drugs. Further research and development can address the unmet need by coming up with drugs that have a convenient dosage schedule with better efficacy and safety compared to traditional treatment of Osteoporosis.
After 2012, the Parathyroid Hormone and SERM Osteoporosis drug class market is expected to decline because of anticipated growth of Prolia (Denosumab), which will eat away other drugs’ market share
|
|
|
|
